A Randomized Single-blind Clinical Trial of the Efficacy and Safety of Remimazolam in Painless Bronchoscopy

NCT ID: NCT04919174

Last Updated: 2021-06-09

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE4
• Total Enrollment: 364 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-04-23
• Study Completion Date: 2022-10-31

Brief Summary

Over the past decade, bronchoscopy technology has developed rapidly and has become an important part of the diagnosis and treatment of respiratory diseases. Bronchoscopy are usually carried out under monitored anesthesia care (MAC), which can relieve the anxiety of the patient, make the operation easier, and improve the completion rate of bronchoscopy. At present, bronchoscopy has widely used midazolam, propofol, short-acting opioids, and newer sedatives such as dexmedetomidine, but each drug has its limitations. Dexmedetomidine is widely used in non-intubation general anesthesia and sedation during short outpatient surgery. However, rapid and high-dose infusion of dexmedetomidine leads to dose-dependent hypotension, temporary hypertension, bradycardia, and excessive sedation, causing hemodynamic fluctuations. At the same time, it has slow onset and metabolism. This may be a potential risk for some elderly patients with many underlying diseases and unstable hemodynamics. Remimazolam is an ultra-short-acting benzodiazepine. It has the advantages of short action time, low accumulation, low risk of respiratory depression, and reversibility. We believe that remimazolam can improve the onset time and resuscitation time, to achieve sufficient sedation, improve the success rate of bronchoscopy, while reducing the patient's oxygen saturation drop during the operation, postoperative opioid-related nausea and vomiting, postoperative delirium and other related adverse events. This study is a randomized controlled trial to confirm the above hypothesis.

Detailed Description

All patients undergoing bronchoscopy under general anesthesia will be recruited and should complete relevant preoperative examinations. The patient fasted for 6-8 hours before the operation, and an indwelling trocar was placed in the vein. After entering the room, the patient will be monitored with electrocardiogram(ECG), pulse oximetry, non-invasive blood pressure, and underwent oxygen inhalation (5L/min) through a nasal cannula. All patients used 2% lidocaine glue to moisten the nasal cavity for local anesthesia before the operation, the bronchoscope was inserted through the nose. The subjects take a supine position. When the bronchoscope passes through the vocal cords and carina, 5 ml of 2% lidocaine is delivered through the channel to suppress the cough reflex. Then the patients were randomly divided into two groups:

1. one group use dexmedetomidine-remifentanil for anesthesia: the initial dose of dexmedetomidine is 0.1ml/kg, infused for 5 minutes, and then adjusted to 0.1-0.5ml/kg/h; the initial dose of remifentanil is 0.05ml/kg, infused for 5 minutes, and then adjusted to 0.1- 0.5 ml/kg/h.

2. the other group use remimazolam-remifentanil for anesthesia: the initial dose of remimazolam is 0.1ml/kg, infused for 5 minutes, and then adjusted to 0.1-0.5ml/kg/h; the initial dose of remifentanil is 0.05ml/kg, infused for 5 minutes, and then adjusted to 0.1- 0.5 ml/kg/h.

All patients started bronchoscopy when they reached TE sedation (modified observer's assessment of sedation,MOAA/S score 3 points). If the assessment of sedation after administration suggests that the sedation is insufficient, propofol 0.4-0.6 mg/kg is repeatedly administered every 5 minutes, with the maximum dose not exceeding 200 mg to maintain sedation. In the maintenance phase of sedation, appropriate sedation is pre-defined as a MOAA/S score of 4 or less. The drug was continuously infused until the end of the bronchoscopy, and all patients were transferred to the post-anaesthesia care unit (PACU) for further observation.

Data from the DoCare Clinic electronic anesthesia recording system was used in this experiment. Bronchoscopy was performed by the same bronchologist with more than 10 years of experience.

Conditions

Bronchoscopy; Sedation

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Control group

Patients receive dexmedetomidine for sedation

Group Type: ACTIVE_COMPARATOR

Dexmedetomidine

Intervention Type: DRUG

Sedation with dexmedetomidine

Test group

Patients receive remimazolam for sedation

Group Type: EXPERIMENTAL

Remimazolam

Intervention Type: DRUG

Sedation with remimazolam

Interventions

Remimazolam

Sedation with remimazolam

Intervention Type: DRUG

Dexmedetomidine

Sedation with dexmedetomidine

Intervention Type: DRUG

Other Intervention Names

Remifentanil; Remifentanil

Eligibility Criteria

Inclusion Criteria

1. 18 to 70 years old.

2. Need for bronchoscopy (for example, unexplained cough, hemoptysis, localized wheezing and hoarseness, chest X-ray and/or CT scans suggest abnormalities, examination and evaluation of lungs before surgery, chest trauma, lungs Or bronchial infectious disease).

3. ASA classification I-III level.

4. BMI≤30kg/m2.

5. Women of childbearing age have a negative pregnancy test.

6. Before the study, the patients voluntarily signed and dated the informed consent form approved by the institutional review board.

Exclusion Criteria

1. Patients with known allergies to benzodiazepines, flumazenil, opioids, naloxone or certain drugs.

2. Patients with long-term use of benzodiazepines or opioids.

3. Patients with a history of drug abuse or alcohol abuse in the past two years.

4. Bradycardia (baseline HR <60bpm) or hypotension (baseline SAP<100mmHg).

5. Asthma or chronic obstructive pulmonary disease(COPD) or FEV1<1.0L.

6. SpO2 <90% before bronchoscopy.

7. Patients who received any study drug within 30 days before screening or less than 7 half-lives of the drug.

8. Any patient with cognitive impairment or inability to provide informed consent.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Min Yan, MD

Role: STUDY_CHAIR

Zhejiang University

Locations

The Second Affiliated Hospital of Zhejiang University Medical College

Hangzhou, Zhejiang, China

Site Status: RECRUITING

Countries

China

Central Contacts

Min Yan, MD

Role: CONTACT

zryanmin@zju.edu.cn

13757118632

Facility Contacts

Min Yan, MD

Role: primary

zryanmin@zju.edu.cn

15888210247

Other Identifiers

2021-0058

Identifier Type: -

Identifier Source: org_study_id